Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Although we’re only half way through the decade, the 2020s has already given rise to some highly memorable – dare I say potentially classic – print ads. Minimal branding, bold photography ...

The Times of India has launched the #AdsWeLove platform, allowing users to explore a range of creative print advertising campaigns. This platform showcases campaigns from publications like The ...

Digital platforms accounted for 63% of total e-commerce advertising spend in 2024, even as overall ad investments in the sector declined, according to a new report by ad-tech agency Excellent ...

BUFFALO, N.Y. — In January, Nicole Albanese, PharmD, clinical associate professor of pharmacy practice in the University at ...

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023. Zepbound's prospects still ...

green up pointing triangle & Co. Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.

Zepbound is a brand-name subcutaneous injection prescribed for weight loss and weight management. Zepbound isn’t known specifically to increase your energy. However, the drug’s effects on ...